Imunon, Inc. IMNN 深 沪
已收盘 05-15 16:00:00 美东时间
2.49
-0.060
-2.35%
华盛通- 最 高2.60
- 今 开2.49
- 成交量 2.22万股
- 最 低 2.395
- 昨 收 2.55
- 总市值 991.85万
- 52周最高 41.2174
- 市盈率 静 --
- 换手率 0.56%
- 52周最低 2.395
- 委 比 -55.38%
- 总股本 398.33万
- 历史最高 25857.3851
- 量 比 0.63
- 振 幅 8.04%
- 历史最低 2.395
- 每 手 1
- 风险率 4.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Imunon Reports Q1 2026 Results: Full Earnings Call Transcript
Imunon (NASDAQ:IMNN) released first-quarter financial results and hosted an ear...
05-12 23:54
Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.07) by 21.5 percent. This is a 73.33 percent increase over losses of $(3.15) per share from the same
05-12 20:01
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
美股大行评级 | 美银证券上调闪迪目标价从900美元升至1080美元；纽约梅隆银行、Onto Innovation、安博、美国合众银行等获多家大行上调目标价
今日重点评级关注：Guggenheim：维持AtaiBeckley Inc."买入"评级，目标价从11美元升至16美元；RBC Capital：维持MeiraGTx Holdings"跑赢大市"评级，目标价从16美元升至24美元
04-20 11:33
Maxim Group Initiates Coverage On Imunon with Buy Rating, Announces Price Target of $10
Maxim Group analyst Jason McCarthy initiates coverage on Imunon (NASDAQ:IMNN) with a Buy rating and announces Price Target of $10.
04-17 21:18
Imunon Q4 EPS $(1.30) Misses $(1.13) Estimate
Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(1.13) by 15.04 percent. This is a 56.67 percent increase over losses of $(3.00) per share from the same
03-31 20:12
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
Watching Imunon; Zacks Small-Cap Research Gives Stock $33 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03252026_IMNN_Bautz.pdf
03-25 23:11
IMUNON Reports Improved Survival In OVATION 2 Trial, With IMNN-001 Extending Overall Survival Up To 24.2 Months
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysisPatients treated with PARP
03-25 20:08
IMUNON Announces $7M Registered Direct Offering Of 1.94M Shares And Warrants Priced At A Combined Price Of $3.61
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused
2025-12-30 21:32
